AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Hantz Financial Services Inc.

Hantz Financial Services Inc. increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,726 shares of the company’s stock after acquiring an additional 1,212 shares during the quarter. Hantz Financial Services Inc.’s holdings in AstraZeneca were worth $2,996,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AZN. Martin Investment Management LLC raised its position in shares of AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares in the last quarter. Nordea Investment Management AB acquired a new stake in AstraZeneca in the fourth quarter valued at $754,000. Diversify Wealth Management LLC boosted its stake in AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after acquiring an additional 153 shares during the last quarter. Ameritas Advisory Services LLC grew its holdings in AstraZeneca by 25.9% during the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock worth $622,000 after acquiring an additional 1,949 shares in the last quarter. Finally, Integrated Advisors Network LLC increased its position in shares of AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after purchasing an additional 13,860 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $71.24 on Friday. The company has a market cap of $220.92 billion, a P/E ratio of 34.09, a PEG ratio of 1.13 and a beta of 0.46. The business has a 50 day moving average of $66.83 and a two-hundred day moving average of $73.99. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the firm posted $0.87 EPS. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. As a group, analysts anticipate that AstraZeneca PLC will post 4.12 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.